

# **EMPOWER CLINICS ANNOUNCES RECEIPT OF OVER \$5,500,000 FROM EXERCISE OF WARRANTS, LAUNCHES NEW CORPORATE WEBSITE FOR FUTURE INTEGRATED HEALTHCARE**

*Warrant Proceeds Received At Perfect Time As KAI Medical Lab Testing Demand Grows, Company Prepares To Launch FDA Approved Saliva-Based COVID-19 Test and Launches new Corporate Website to Showcase Integrated Healthcare future*

**VANCOUVER BC: December 14, 2020 – EMPOWER CLINICS INC. (CBDT:CSE) (SEC:Frankfurt) (EPWCF:OTCQB)** (“Empower” or the “Company”) an integrated healthcare company serving patients through its clinics, telemedicine platforms and as a leading medical diagnostics laboratory processing thousands of COVID-19 specimens and developing novel COVID-19 testing protocols for CE, FDA and Health Canada approval is pleased to announce the following:

## **RECEIPT OF \$5,500,000 + FROM THE EXERCISE OF WARRANTS ALLOWS EMPOWER TO CONTINUE TO EXECUTE WITH INCREASED STRENGTH**

Empower is pleased to announce the receipt of in excess of \$5,500,000 from the exercise of warrants up to December 11, 2020. The proceeds were received over the past four trading days as a result of strong equity market support for the momentum demonstrated by the Company. It serves as an indication of the strength of Empower’s shareholder base and its following.

The Company expects to generate meaningful revenue from its current and anticipated sales pipeline over the next 12 months, as well as, receive additional proceeds from further anticipated warrant exercises, the Company is confident it has the war chest necessary to pursue numerous opportunities. KAI medical laboratory continues to expand nationwide in the U.S., Empower is growing physician services and direct access to patients through new clinics expansions and the company will provide dynamic technology-based healthcare services to meet patient needs.

Steven McAuley, Chairman and CEO of Empower stated, “The timing of these warrant exercises could not be better as we head into our biggest growth phase ever, thanks to rapidly growing demand for our KAI Medical Lab COVID-19 testing solutions, as well as, the impending launch of our FDA approved KAI Saliva Test plus the pending clinic group acquisition in Canada. These proceeds significantly bolster our financial strength, resources and confidence necessary to aggressively pursue our growth strategies in 2021.”

## **EMPOWER LAUNCHES NEW WEBSITE TO BETTER REFLECT COMPANY’S 2021 DIRECTION**

The Company is pleased to report that our new website has been launched to reflect the Company’s pillars of growth in 2021 and beyond, as well as, our defined vision as follows:

### GROWTH PILLARS

**Health & Wellness Is Our Purpose** - Through our clinics in the US and telemedicine platform, our physicians treat patients in Oregon, Arizona and Washington State. Within this section you can read our statements about Integrated Care, Patient First and Rapid Expansion.

**Diagnostics & Tech Is Our Vision** - The October 5th acquisition of Texas-based KAI Medical Laboratory was a significant achievement for Empower, as it firmly and immediately established the science and research side of Empower. In its first month, KAI delivered record revenues and soon after announced its first \$1,000,000 COVID-19 testing contract for a major film and television studio.

This section is rich in information for investors that want to better familiarize themselves with the capabilities of KAI Laboratory and COVID-19 testing capabilities that attracted major contracts and R&D initiatives.

We invite all of our shareholders and prospective investors to visit our new website at <https://www.empowerclinics.com/>

### **EMPOWER TO COMMENCE VERIFIED DISCUSSIONS BY CEO AND KEY PERSONNEL ON AGORACOM**

The Company is commencing discussions on its "CEO Verified Forum" on AGORACOM, which is intended to serve as one of the Company's social media platforms for interaction with current and prospective shareholders.

Steven McAuley added "The growth experienced by Empower over the past 12 months has come from all sources providing the best possible engagement with our clients, followers, investors and all social platforms. I enjoy responding to shareholder inquiries, and the demand for engagement and discussion by investors has grown significantly. Engaging with Agoracom followers is an invaluable tool given our anticipated developments and I look forward to posting my comments and interactions with shareholders."

The Empower Clinics Verified Forum can be found at <https://agoracom.com/ir/EmpowerClinics/forums/discussion>

### **About Empower**

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients and provide long term value for our shareholders.

### **ON BEHALF OF THE BOARD OF DIRECTORS:**

Steven McAuley  
Chief Executive Officer

### **CONTACTS:**

Investors:

Steven McAuley  
CEO  
[s.mcauley@empowerclinics.com](mailto:s.mcauley@empowerclinics.com)  
604-789-2146

Dustin Klein  
Director  
[d.klein@empowerclinics.com](mailto:d.klein@empowerclinics.com)  
720-352-1398

#### DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

*This news release contains certain "forward-looking statements" or "forward-looking information" (collectively "forward looking statements") within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as "plans", "continues", "expects", "projects", "intends", "believes", "anticipates", "estimates", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley's franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company's products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company's business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company's control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.*